deltatrials
Unknown PHASE2 NCT03986515

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Clinical Study of SHR-1210 Plus Apatinib in Patients With Advanced Mucosal Melanoma Whose Diseases Progress After Chemotherapy

Sponsor: Henan Cancer Hospital

Conditions Advanced Cancer Apatinib Mucosal Melanoma SHR-1210
Interventions apatinib plus SHR-1210
Updated 5 times since 2019 Last updated: Jun 11, 2019 Started: Jun 4, 2019 Primary completion: May 31, 2021 Completion: May 31, 2022

A PHASE2 clinical study on Advanced Cancer and Apatinib, this trial is ongoing. The trial is conducted by Henan Cancer Hospital and has accumulated 5 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jul 2022 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  4. Jan 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  5. Jul 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Henan Cancer Hospital
Data source: Henan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Zhengzhou, China